Get started
Author

Jeffrey Drajesk

Observed names: J Drajesk, J F Drajesk, J. Drajesk, Jeff Drajesk
OpenAlex ID: A5024252688
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment
1999 · Jeffrey M. Drazen, Chandri N. Yandava, et al. · Nature Genetics · 556
Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T- cell lymphoma
1991 · CF LeMaistre, S Rosen, et al. · Blood · 115
The Effect of ABT-761, a Novel 5-Lipoxygenase Inhibitor, on Exercise- and Adenosine-Induced Bronchoconstriction in Asthmatic Subjects
1997 · J Van Schoor, G F Joos, et al. · American Journal of Respiratory and Critical Care Medicine · 51
Pharmacokinetics of Zileuton and Its Metabolites in Patients with Renal Impairment
1997 · Walid M. Awni, Shekman Wong, et al. · The Journal of Clinical Pharmacology · 14
Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers
1998 · Shekman L. Wong, Jeffrey Drajesk, et al. · Clinical Pharmacology & Therapeutics · 9
Dose-proportional pharmacokinetics of a new 5-lipoxygenase inhibitor, ABT-761, in healthy volunteers
1998 · Shekman L. Wong, Jeffrey Drajesk, et al. · Biopharmaceutics & Drug Disposition · 4
Clinical Observation of Liver Chemistry Abnormalities in Asthmatics
2009 · David Katz, Jeffrey Isaacson, et al. · Current Drug Safety · 3
Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma
1998 · S. L. Wong, G. L. Kearns, et al. · European Journal of Clinical Pharmacology · 1
PMON72 The "RESCUE" Trial: 11beta-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition for ACTH-Dependent Cushing's Syndrome
2022 · Frank S Czerwiec, Jeffrey Drajesk, et al. · Journal of the Endocrine Society
PDF
PSUN20 The ACSPIRE Trial: 11beta-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition for Autonomous Cortisol Secretion and Adrenal Cushing's Syndrome
2022 · Frank S Czerwiec, Jeffrey Drajesk, et al. · Journal of the Endocrine Society
PDF
The ACSPIRE trial: 11[beta]-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibition for autonomous cortisol secretion and adrenal cushing's syndrome
2022 · Frank Czerwiec, Jeffrey Drajesk, et al. · Endocrine Abstracts
The [ldquo]RESCUE[rdquo] Trial: 11[beta]-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition for ACTH-Dependent Cushing's Syndrome
2022 · Frank Czerwiec, Jeffrey Drajesk, et al. · Endocrine Abstracts
Relationship between genotype at the 5-lipoxygenase core promoter locus and the clinical response to ABT-761
1999 · Drazen Jeffrey, Chandri Yandava, et al. · Prostaglandins & Other Lipid Mediators
Works count: 13
Citation count: 753
H-index: 5
I10-index: 4
Year
Topic
Type